Collectively, we confirmed that the increased number of B cell subclasses IgG1 and IgG3 and CD4+ T cells, and increased level of IL-21 in responder tumor lesions, played critical roles in shaping anti-tumor immune responses and the positive therapeutic response of neoadjuvant chemoimmunotherapy in clinic. The gene discussed is CD4; the disease is neoplasm.